This is an old revision of this page, as edited by Meodipt (talk | contribs) at 08:17, 31 March 2009. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 08:17, 31 March 2009 by Meodipt (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundChemical and physical data | |
---|---|
Formula | C20H19NO5 |
Molar mass | 353.37 g/mol g·mol |
LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3-selective LY-341,495.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |
References
- Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology. 2000 Sep;131(2):239-44. PMID 10991916